骨质疏松症治疗药物合理应用专家共识(2023)  

Expert consensus on rational use of anti-osteoporosis agents (2023)

作　　者：中国药学会医院药学专业委员会 《骨质疏松症治疗药物合理应用专家共识(2023)》编写组 张玉[2] 游如旭 张聪 Hospital Pharmacy Committee of Chinese Pharmaceutical Association,Compilation Group of Eapert Consensus on Rational Use of Anti-Osteoporsis Agents(2023)

机构地区：[1]不详 [2]华中科技大学同济医学院附属协和医院,湖北省重大疾病精准用药临床医学研究中心,武汉430022 [3]华中科技大学同济医学院附属协和医院

出　　处：《中国医院药学杂志》2024年第9期985-1006,共22页Chinese Journal of Hospital Pharmacy

摘　　要：骨质疏松症(osteoporsis,OP)是最常见的骨骼疾病,是一种以骨量低、骨组织微结构损坏所导致骨脆性增加并易发生骨折为特征的全身性骨病。随着我国社会人口老龄化的加剧,OP的患病率大幅攀升,但其知晓率、诊断率和治疗率均偏低。骨质疏松性骨折是其严重后果,尤其在老年人中,可导致残疾和死亡,并且相关医疗和护理成本巨大。OP及其骨折已经成为我国所面临的重要公共健康问题。OP治疗药物按照作用机制可分为骨吸收抑制剂、骨形成促进剂、双重作用药物和其他机制类药物。为了规范OP治疗药物的合理应用,提升治疗效果和患者满意度,中国药学会医院药学专业委员会基于当前OP治疗药物的临床研究和应用现状,组织多学科专家讨论并联合制定了本共识。Osteoporosis has been the most prevalent bone disease.It is characterized clinically by systemic low bone mass and microstructural damage to bone tissue,resulting in heightened vulnerability to fractures due to greater bone fragility.With a rapid aging of society,the prevalence of osteoporosis has markedly spiked.However,its public awareness,diagnostic rate and treatment level remain low.Osteoporotic fractures carry severe consequences,particularly among elders,leading to disability and even death.Consequently,osteoporosis and associated fractures have emerged as critical public health issues in China.Anti-osteoporosis agents may be divided into anti-resorptives,anabolics of stimulating bone formation and dual-acting drugs.Based upon the latest clinical trials and drug application status for osteoporosis,a multidisciplinary panel of experts assembled by Hospital Pharmacy Committee of Chinese Pharmaceutical Association has collaborated to develop this consensus for standardizing rational drug dosing for improved patient outcomes and satisfactions.

关 键 词：OP治疗药物 合理应用 专家共识 

分 类 号：R969.3[医药卫生—药理学]